Bellevue Group AG

Q2 2019 13F Holdings Report, Stock Holdings

Signature - Title
Christoph Eisenring / Stefano Montalbano - Head Legal & Compliance / CFO
Location
Kuesnacht, Switzerland
Holdings as of
June 30, 2019
Value $
$5.86B
Num holdings
201
Date filed
8/14/2019, 02:28 PM
Description
All US holdings of this investor are reported in this report. The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as of the end of the calendar quarter for which the report is filed, and the total market value. The market value column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in accounts.
Previous filing
Q1 2019 - May 15, 2019
Next filing
Q3 2019 - Nov 14, 2019
Options Holdings
Showing stock holdings, see here for options holdings
Sym Weight Trade Impact Company Class Shares Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2019 Q2 compared to 2019 Q1 by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Michael Hutter CFO Kuesnacht, Switzerland 8/13/2019

Other Included Managers (6):

Num Name Location File Number
1 BB BIOTECH AG Schaffhausen, Switzerland 028-06964
2 Biotech Focus N V 028-11193
3 Biotech Invest N V 028-11191
4 Biotech Target N V 028-11189
5 Biotech Growth N V 028-11194
6 Bellevue Asset Management AG Kuesnacht, Switzerland 028-16892